Purpose To synthesize and evaluate a peptide targeted nanoglobular dual modal imaging agent specific to a cancer biomarker in tumor stroma for MRI and fluorescence visualization of prostate tumor in image-guided surgery.
INTRODUCTION
Accurate detection and localization of malignant tumors is crucial to improve effectiveness of cancer treatments and interventions. Various imaging modalities, including X-ray computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET) and single photon emission computed tomography (SPECT), have been broadly used in the clinical practice for cancer detection and diagnosis. Recently, intraoperative optical imaging has been developed to assist tumor localization and to guide surgical tumor resection (1) (2) (3) . The combination of non-invasive anatomic diagnostic imaging and intraoperative optical imaging would be valuable for accurate tumor localization and imageguided surgery. MRI is a non-ionizing imaging modality and provides three-dimensional high-resolution images of soft tissues. Contrast enhanced MRI with a tumor specific contrast agent can non-invasively detect malignant tumors before surgery interventions. Fluorescence imaging has high sensitivity for detecting cancer biomarkers and can accurately delineate tumor boundary to guide tumor resection based on the cancer related biomarkers.(4-6) The design and development of a tumor specific molecular imaging agent containing both an MRI contrast agent and a fluorescence dye will enable the combination of two imaging modalities for tumor detection localization by MRI and image-guided surgery by fluorescence imaging.
Various dual imaging agents containing both MRI contrast agent and fluorescence dye have been reported in the literature. We have recently reported that CLT1 peptide (CGLIIQKNEC) targeted nanoglobular Gd-DOTA monoamide conjugates are effective for MR cancer molecular imaging of a cancer related biomarker in tumor stroma. (14, 15) CLT1 is a cyclic peptide and specifically binds to the fibrin-fibronectin complexes in the extracellular matrix of different tumors with little binding to normal tissues. (16) Nanoglobules, lysine dendrimers with a silsesquioxane core, are a unique class of dendrimers with high surface functionality, nanoscopic dimension and well-defined structure. (17) The high surface functionality allows the conjugation of the peptide, a relatively large number of Gd-DOTA monoamide and other imaging probes. (15) The peptide targeted generation 2 (G2) nanoglobular conjugate produced strong enhancement in tumor tissue, including orthotopic prostate tumor, at a reduced dose (0.03 mmol-Gd/kg). (15, 18) Its relatively small size (ca. 5.6 nm) allows rapid excretion of free conjugate via renal filtration, resulting in minimal tissue Gd retention.
Herein, we report the synthesis and evaluation of a CLT1 peptide targeted G2 nanoglobular Gd-DOTA monoamide and cyanine 5 conjugate CLT1-G2-(Gd-DOTA-MA)-Cy5 as a targeted dual imaging agent. The targeted nanoglobular dual imaging agent was synthesized by stepwise conjugation of Gd-DOTA monoamide, Cy5 and peptide. Tumor MRI and fluorescence imaging of the dual-imaging agent was investigated at a dose of 30 μmol-Gd/kg in athymic mice bearing orthotopic PC3-GFP prostate tumor. Synthesis of G2 Nanoglobule-(Gd-DOTA) 20 -(lysine-PEG-N 3 ) 3 Conjugate. (Compound 3)
MATERIALS AND METHODS
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G2 nanoglobule-(lysine-PEG-N 3 ) 3 conjugate (136 mg, 13 μmol), DOTA-tris(t-Bu) (416 mg, 728 μmol), HBTU (276 mg, 728 μmol), HOBt (98 mg, 728 μmol) and DIPEA (0.5 mL) were dissolved in DMF (3 mL) and stirred at room temperature for 60 h. After reaction, the product was added to anhydrous diethyl ether. The oil-like precipitate was washed several times with diethyl ether and the protecting groups were removed by dissolving the precipitate in a mixture of TFA and dichloromethane (5 mL, volume/volume = 1:1) for 4 h while stirring at room temperature. The residue was treated with ice-cold diethyl ether to give a colorless solid. The precipitate was dissolved in pure water and further purified by ultrafiltration using Millipore's Amicon® Ultra-15 centrifugal filters (3 kDa molecular weight cutoff). A Kaiser test was then performed to confirm the presence of primary amine groups. Yield of G2 nanoglobule-(DOTA) 20 -(lysine-PEG-N 3 ) 3 G2 nanoglobule-(DOTA) 20 -(lysine-PEG-N 3 ) 3 conjugate (152 mg, 10.8 μmol) in 4.0 mL deionized water was mixed with Gd(OAc) 3 (765 mg, 1.66 mmol) and stirred at room temperature for 4 days. The excess free Gd 3+ ions were removed from the solution by adding EDTA and eluting through a PD-10 desalting column with deionized water. The product G2 nanoglobule-(Gd-DOTA) 20 -(lysine-PEG-N 3 ) 3 conjugate was further purified by dialysis with a membrane with a molecule weight cutoff of 1,000 Da at room temperature. Yield of G2 nanoglobule-(Gd-DOTA) 20 -(lysine-PEG-N 3 ) 3 was 31 mg, 64%. A Kaiser test was then performed to confirm the presence of primary amine groups on the compound 3.
Synthesis of G2 Nanoglobule-(Gd-DOTA) 20 -(lysine-PEG-N 3 ) 3 -Cy5 Conjugate. (Compound 4) G2 nanoglobule-(Gd-DOTA) 20 -(lysine-PEG-N 3 ) 3 conjugate (36 mg, 2 μmol), Cy5 mono-NHS ester (5 mg, 7.2 μmol), PyBOP (11 mg, 21.6 μmol), HOBt (3 mg, 21.6 μmol) and DIPEA (20 μL) were dissolved in DMSO (1 mL) and stirred at room temperature for 24 h. After reaction, the product was added to water and the hydrophobic impurities were removed by filtration. The filtrate was purified by ultrafiltration using Millipore's Amicon® Ultra-15 centrifugal filters (3 kDa molecular weight cutoff). Yield of G2 nanoglobule-(Gd-DOTA) 20 -(lysine-PEG-N 3 ) 3 -Cy5 conjugate was 34 mg, 87%. The number of Cy5 attached onto G2 nanoglobular conjugate was approximately one on average as determined by UV spectroscopy.
CLT1 peptide was conjugated to G2 nanoglobule-(Gd-DOTA) 20 -(lysine-PEG-N 3 ) 3 -Cy5 conjugate via "click chemistry" between the reactive propargyl group of the peptide conjugate (15) and azido group of the nanoglobule-(Gd-DOTA) 20 -(lysine-PEG-N 3 ) 3 -Cy5 conjugate. G2 nanoglobule-(Gd-DOTA) 20 -(lysine-PEG-N 3 ) 3 -Cy5 conjugate (54 mg, 2.0 μmol) and ascorbic acid (3.6 mg, 2.0 μmol) were dissolved in 2 mL water, followed by the addition of copper(II) sulfate pentahydrate (0.5 mg, 2.0 μmol). Then peptide-PEG-propargyl conjugate (23 mg, 16 μmol) in 2 mL of DMSO/tert-butyl alcohol (1:1, v/v) was added to above solution and the reaction was stirred vigorously for 40 h at room temperature. The precipitate was removed by filtration. The product was purified by ultrafiltration and dialysis (molecule weight cutoff = 1,000 Da) at room temperature to remove any small molecular impurities. Yield of the peptide dual imaging agent CLT1-G2-(Gd-DOTA-MA)-Cy5 was 20 mg, 32.9%. The Gd(III) content measured by inductively coupled plasma optical emission spectroscopy (ICP-OES Optima 3100XL, Perkin-Elmer) was 10.37% wt/wt. The Cy5 content in the conjugate was determined by UV spectrophotometry. There were three peptides in each conjugate on average as estimated from sulfur content determined by ICP-OES.
Synthesis of Control Agent KAREC-G2-(Gd-DOTA-MA)-Cy5
The control peptide KAREC modified G2 nanoglobular agent KAREC-G2-(Gd-DOTA-MA)-Cy5 was similarly prepared as described in "Synthesis of CLT1-G2-(Gd-DOTA-MA)-Cy5 (Compound 5)" by reacting KAREC-PEGpropargyl conjugate (2.2 mg, 2.4 μmol) with compound 4 (12 mg, 0.4 μmol). The yield of the final product KAREC-G2-(Gd-DOTA-MA)-Cy5 was12.84 mg, 99%. The Gd(III) content measured by ICP-OES was 10.50% wt/wt. There were three peptides in each conjugate on average as estimated from sulfur content determined by ICP-OES.
Orthotopic PC3 Prostate Tumor Model
PC3 human prostate adenocarcinoma cells were cultured in Roswell Park Memorial Institute (RPMI) medium supplemented with 5% fetal bovine serum and penicillin/streptomycin/fungizone. The cells were infected with lentivirus to express green fluorescent protein (GFP) at least 48 h prior to harvesting. PC3-GFP Cells were harvested for prostate implantation by trypsinization and concentrated in RPMI medium. The cell suspension was loaded into a syringe fitted with a 27 gauge needle. NIH athymic nude male mice, age 4-5 weeks, were maintained at the Athymic Animal Core Facility at Case Western Reserve University according to institutional guidelines. All animal protocols were approved by the Institutional Animal Care and Use Committee (IACUC). Mice were anesthetized by intraperitoneal injection of Avertin. A small midline incision was made through the skin and underlying musculature in the abdominal region overlying the bladder. The bladder was reflected through the incision to expose the prostate gland. Approximately 20 μl concentrated PC3-GFP cells were injected into the prostate, and the incision was closed with staples. The staples were removed 10 days later. The growth of PC3-GFP prostate tumor was monitored using the Maestro FLEX In Vivo Imaging System after cell injection.
Contrast Enhanced MR Tumor Imaging
After the tumor size reached about 0.3-0.5 cm in diameter, MRI study was carried out on a Bruker Biospec 7T MRI scanner (Bruker Corp., Billerica, MA, USA) with a volume radio frequency (RF) coil. The mice were randomly divided into groups (N = 4) for MR molecular imaging study. Animals were anesthetized with 2% isoflurane with supplemented O 2 continuously during the whole imaging process via a nose cone. Electrodes were attached to front paws and right leg for ECG monitoring vital signs through an MRcompatible small animal gating and monitoring system (SA Instruments, Stony Brook, NY). The anesthetized animals' body temperature was maintained at 35±1°C by blowing hot air into the magnet through a feedback control system. The heat flow and the anesthesia level were manually adjusted to maintain the heart rate close to that under conscious condition. A 30-gauge needle was inserted into the tail vein and connected to a syringe through a flexible plastic tubing (Tygon®, Saint-Gobain PPL Corp. Akron, OH) for contrast agent administration. The dual-imaging agents were administered via the tail vein at a dose of 30 μmol-Gd/kg body weight.
The mice were scanned before the injection and at 1, 5, 10, 15, 20, 25, 30, 35, and 40 min post-injection using Bruker gradient-echo T 1 -weighted MRI sequence (TR/TE = 151.2/1.9 ms, number of averages = 1, flip angle = 30°, total acquisition time = 19 s, slice thickness = 1.2 mm, field of view = 3.0 cm, matrix = 256×256, slice number = 12). Image analysis was performed using Bruker ParaVision 4.0 imaging software. Regions of interest were drawn over the whole tumor in the 2D images. Signal intensity (S) was measured at each time point and averaged from the tumors of the mice (N=4). The signal to noise ratio (SNR) was calculated using the following equation: SNR ¼ S À S 0 ð Þ σ n = ; where S (post-injection) and S 0 (preinjection) denote the signal within the regions of interest (ROIs) and σ n is the standard deviation of noise estimated from the background air. Statistical analysis was performed using a two-way ANOVA with Bonferroni's, assuming statistical significance at p<0.05.
Tumor Fluorescence Imaging
Fluorescence imaging of PC3-GFP prostate tumor was performed on a Maestro FLEX In Vivo Imaging System using the appropriate filters for GFP (excitation: 444-490 nm; emission: 515 nm long-pass filter; acquisition settings: 500-720 in 10 nm steps) and Cy5 (excitation: 576-621 nm; emission: 635 nm long-pass filter; acquisition settings: 630-800 in 10 nm steps). Acquisition settings were 10 ms for GFP and 61 ms for the Cy5 conjugates. The mice were sacrificed 2 h after the intravenous injection of CLT1-G2-(Gd-DOTA-MA)-Cy5 and KAREC-G2-(Gd-DOTA-MA)-Cy5 (10 nmol Cy5 per mouse). Both GFP and Cy5 fluorescence images of the tumor and various organs were then acquired. The fluorescent signal was spectrally separated from the multispectral fluorescence images with Maestro software (Cambridge Research & Instrumentation, Inc, Woburn, MA) to subtract the background autofluorescence.
RESULTS
Synthesis of the Dual Modal Imaging Agent
The synthesis of the peptide targeted dual imaging agent CLT1-G2-(Gd-DOTA-MA)-Cy5 and the control agent KAREC-G2-(Gd-DOTA-MA)-Cy5 is shown in Scheme 1. The azido-PEG and lysine conjugate (compound 1) was synthesized as a bifunctional linker for the conjugation of the targeting peptide and cyanine 5. G2 nanoglobule had 32 surface amino groups for conjugation of the targeting agent and imaging agents. In order to maximize conjugation degree of Gd-DOTA-MA to the dendrimer and minimize possible fluorescence quench of Cy by the Gd(III) chelates, Cy5 was conjugated to the ε-amino group of lysine in the compound 1 after conjugation of Gd-DOTA-MA. Approximately 3 linker molecules and 20 DOTA-MA chelates on average were conjugated to each dendrimer. Approximately 63% of the amino groups were conjugated with DOTA-MA even in the presence of an excess of the ligands. The presence of free amino group in the nanoglobular conjugate was confirmed by Kaiser test. Gadolinium(III) was then reacted with nanoglobular ligands at room temperature for 4 days to assure complete complexation of the ligand. Approximately one Cy5 molecule was conjugated to the ε-amino group of the lysine residues on the linker after the deprotection. Finally, three peptide molecules (CLT1 or KAREC) was conjugated to the dendrimer via click chemistry. Less Cy5 molecule was conjugated to the dendrimer than the peptides, possibly because of the steric effect of the PEG and dendrimer in the conjugation reaction with Cy5 active ester.
The physicochemical parameters of the dual-imaging agents are listed in Table I 
Contrast-Enhanced MR Tumor Imaging
The effectiveness of the targeted dual imaging agent CLT1-G2-(Gd-DOTA-MA)-Cy5 in contrast enhanced MR tumor imaging was demonstrated in male nude mice bearing orthotopic prostate tumor. Figure 1 shows the T 1 -weighted 2D axial MR images of the orthotopic prostate tumor contrast enhanced with CLT1-G2-(Gd-DOTA-MA)-Cy5 and KAREC-G2-(Gd-DOTA-MA)-Cy5. The targeted agent CLT1-G2-(Gd-DOTA-MA)-Cy5 resulted in strong enhancement in the tumor tissue, particularly in the tumor periphery at 5 min post-injection. The enhancement gradually decreased over time, but substantial enhancement was still visible at 40 min post-injection. KAREC-G2-(Gd-DOTA-MA)-Cy5 also produced visible enhancement in tumor periphery due to the passive EPR effect. However, the tumor enhancement with KAREC-G2-(Gd-DOTA-MA)-Cy5 was weaker than that with CLT1-G2-(Gd-DOTA-MA)-Cy5. The tumor per Gd] at 1. 
DISCUSSION
The concept of using multiple modalities in conjunction with cancer treatment has drawn great attention to utilize the complementary abilities of different imaging modalities to achieve better treatment or intervention under imaging guidance. (9, 19, 20) In the study, we have synthesized and evaluated a peptide targeted nanoglobular dual modal imaging agent for cancer molecular imaging with MRI and fluorescence imaging. The nanoglobules are a class of highly branched lysine dendrimers with high surface functionality and precisely controlled sizes, suitable for conjugation of multiple imaging agents and biologically active agents. (15, 17, 21, 22) The nanoglobules have more surface functional groups than other dendrimers, e.g., PAMAM dendrimers, of the same generation. High surface functional groups allow the conjugation of the targeting agent, fluorescence dye and a relatively large number of Gd-DOTA-MA chelates. CLT1 peptide was developed for targeting the fibrinfibronectin complexes in tumor stroma in various cancers. (16) It has been reported that fibronectin is highly expressed in prostate cancer, much higher than in benign tumors and normal prostate tissue.(23) Our previous study showed that the peptide could specifically bind to the orthotopic prostate tumor tissue. (18) A competitive study also showed that the presence of an excess of free peptide could reduce the binding of a CLT1 targeted imaging agent in tumor tissue. (24) The CLT1 peptide could be an effective targeting agent for the development of targeted dual modal imaging agent for cancer molecular imaging with MRI and fluorescence imaging. As compared with monoclonal antibodies, the use of small molecular CLT1 peptide may reduce the immune reaction caused by the exogenous antibodies and minimize the overall size of the targeted dual imaging agent to facilitate complete elimination of the unbound agent from the body via renal filtration. Complete excretion of Gd(III) based contrast agents is necessitated for their safety in clinical development.
The targeted nanoglobular dual-imaging agent CLT1-G2-(Gd-DOTA-MA)-Cy5 had a high T 1 relaxivity and produced greater enhancement in the periphery of orthotopic prostate cancer than KAREC-Cy5-G2-DOTA-Gd. Since the r 1 relaxivities of both agents are similar, the strong enhancement in tumor with the CLT1 targeted agent should be attributed to the specific binding of the agent in the tumor. The targeted agent also provided better delineation of the boundary of the tumor tissue. MRI provides high-resolution 3D anatomic images of soft tissues. Better tumor delineation would allow more accurate construction of three-dimensional tumor volumes, which could be useful for better planning surgical procedures.
Fluorescence imaging of the dissected tumor tissues showed the overlap of the red fluorescence of Cy5 from the targeted conjugate with GFP from the tumor. The binding of the peptide to the fibrin-fibronectin complexes in tumor stroma allowed tumor visualization with fluorescence imaging 2 h after the injection of the targeted dual imaging agent. The targeted agent also showed significant non-specific binding in the lung. However, such non-specific binding was not observed with CLT1-Cy5 conjugate in our previous study. (15) The non-specific binding of the targeted nanoglobular dual imaging agent could be caused by the relatively large size of the agent and free amines due to incomplete surface conjugation. It was previously reported that positive charged nanosized materials had a high tendency for non-specific accumulation in the lung. (25) (26) (27) Further structure optimization of the targeted dual imaging agents is necessary to minimize non-specific tissue accumulation. We have shown in the a recent study that a CLT1 peptide targeted Gd-DOTA-MA conjugate of a low molecular weight was also effective to produce significant tumor enhancement in the orthotopic prostate cancer model at the same reduced dose. The design of a small molecular CTL1 targeted dual imaging agent may be a possible approach to minimize non-specific tissue accumulation of the targeted dual imaging agent.
We have shown in this study that the combination of MRI and fluorescence imaging based on a targeted dual modal imaging agent has a potential for non-invasive tumor localization and intraoperative tumor fluorescence imaging for image-guide surgery. Contrast enhanced MR tumor imaging with a targeted agent specific to an abundantly expressed cancer biomarker can provide high resolution three dimensional visualization of tumor volume for noninvasive tumor localization and surgical planning. Intraoperative fluorescence imaging with the targeted agent can assist the operating surgeon delineate tumor boundary during the procedure. A safe and effective targeted dual modal imaging agent with high tumor specificity and binding affinity is essential for image-guided surgery. Structural optimization of the targeted dual imaging agent will be performed in the future studies to improve its tumor specificity and binding affinity.
CONCLUSIONS
A peptide targeted nanoglobular dual modal imaging agent CLT1-G2-(Gd-DOTA-MA)-Cy5 was synthesized for cancer molecular imaging with MRI and fluorescence imaging. The targeted agent resulted in significant contrast enhancement in the orthotopic prostate tumor in mice at a relatively low dose as compared to the non-targeted control KAREC-G2-(Gd-DOTA-MA)-Cy5. The targeted dual imaging agent also produced significant fluorescence signal in the tumor tissue. Structural optimization is needed to improve tumor specificity and binding affinity of the targeted dual imaging agent. The combination of MRI and fluorescence imaging based on an effective targeted dual imaging agent has a potential for accurate tumor detection and localization in image-guided cancer surgery.
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